新冠病毒变异株B.1.429和B.1.351的中和作用 - Suppr

Suppr

超能文献

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.

作者信息

Shen Xiaoying, Tang Haili, Pajon Rolando, Smith Gale, Glenn Gregory M, Shi Wei, Korber Bette, Montefiori David C

机构信息

Duke University, Durham, NC

Moderna, Cambridge, MA.

出版信息

N Engl J Med. 2021 Jun 17;384(24):2352-2354. doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7.

DOI:10.1056/NEJMc2103740

PMID:33826819

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8063884/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bb6/8063884/7e9632e6fc41/NEJMc2103740_f1.jpg

相似文献

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.

N Engl J Med. 2021 Jun 17;384(24):2352-2354. doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7.

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.

N Engl J Med. 2021 Jun 17;384(24):2354-2356. doi: 10.1056/NEJMc2103022. Epub 2021 Apr 6.

Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.

EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.

N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).

N Engl J Med. 2021 Jun 3;384(22):2161-2163. doi: 10.1056/NEJMc2104192. Epub 2021 Apr 7.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.

Neutralizing Activity of BNT162b2-Elicited Serum.

N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.

Lancet Infect Dis. 2021 Aug;21(8):1071-1072. doi: 10.1016/S1473-3099(21)00287-5. Epub 2021 May 27.

Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies.

Signal Transduct Target Ther. 2024 May 9;9(1):123. doi: 10.1038/s41392-024-01849-6.

引用本文的文献

Epitope Profiling of SARS-CoV-2 Spike Antigen Provides a Novel Strategy for Developing ELISAs Specific for Different Spike Protein Variants in Bivalent Vaccine Formulations.

Vaccines (Basel). 2025 Jul 26;13(8):794. doi: 10.3390/vaccines13080794.

Production of SARS-CoV-2 virus-like particles as a vaccine candidate in stable cell lines through inducible E and M protein expression.

BMC Biotechnol. 2025 Jul 28;25(1):79. doi: 10.1186/s12896-025-01016-x.

Multi-Antigen Viral-Vectored Vaccine Protects Against SARS-CoV-2 and Variants in a Lethal hACE2 Transgenic Mouse Model.

Vaccines (Basel). 2025 Apr 15;13(4):411. doi: 10.3390/vaccines13040411.

Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques.

Vaccines (Basel). 2024 Apr 10;12(4):404. doi: 10.3390/vaccines12040404.

Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.

Diseases. 2024 Jan 18;12(1):29. doi: 10.3390/diseases12010029.

Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.

Front Immunol. 2023 Dec 12;14:1264323. doi: 10.3389/fimmu.2023.1264323. eCollection 2023.

A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection.

Cell Rep Med. 2023 Dec 19;4(12):101305. doi: 10.1016/j.xcrm.2023.101305. Epub 2023 Nov 30.

In silico prediction of immune-escaping hot spots for future COVID-19 vaccine design.

Sci Rep. 2023 Aug 18;13(1):13468. doi: 10.1038/s41598-023-40741-1.

ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus.

Front Microbiol. 2023 Jul 13;14:1199561. doi: 10.3389/fmicb.2023.1199561. eCollection 2023.

Genomic Diversity and Evolution of SARS-CoV-2 Lineages in Pakistan.

Viruses. 2023 Jun 27;15(7):1450. doi: 10.3390/v15071450.

本文引用的文献

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.

N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.

Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.

Emergence of a Novel SARS-CoV-2 Variant in Southern California.

JAMA. 2021 Apr 6;325(13):1324-1326. doi: 10.1001/jama.2021.1612.

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验